Lilly unites caring with discovery to create medicines that make life better for people around the world. Over 140 years and nearly 100 medicines later, we continue to seek the next great discovery and to uncover even more ways to make life better for people around the world.
T2D injectables: 1. Intensifying to first injectable therapy in uncomplicated type 2 diabetes
This education module focuses on a case study of an uncomplicated patient with type 2 diabetes, and the process of intensifying to first injectable therapy. Expert video commentary throughout the module helps step the participant through the decision cycle from the ADA/EASD consensus guidelines for T2D. This module also includes Australian recommendations for patients fasting during Ramadan.
T2D injectables: 2. Intensifying to first injectable therapy in patients with ASCVD risk
In this education module, the participant will work through a case study of a type 2 diabetes patient with ASCVD risk factors. The case study uses the decision cycle from the ADA/EASD consensus guidelines for T2D, and features expert video commentary. The module also discusses patient-related concerns leading to clinical inertia, including useful management decisions when faced with this issue.
T2D injectables: 3. Intensifying to first injectable therapy in patients with established ASCVD
This education module takes a case-study based look at the management of a type 2 diabetes patient with established ASCVD. Featuring expert video commentary, participants will use the decision cycle from the ADA/EASD consensus guidelines for T2D to work through a hypothetical case study. This module also discusses GP-related causes of clinical inertia, as well as additional patient factors such as obesity, low health literacy and diabetes distress.
GPCE MEDTalks 2020 - Does insulin still have a place in the management of hyperglycaemia in T2D?
Watch the recording of this lively and entertaining MEDTalk presented by three prominent GPs with deep expertise in diabetes as they debate whether, in this new realm of diabetes management, the older sovereign, insulin, should now be consigned to the retirement village of history.
Rethinking first injectable therapies in type 2 diabetes: A practical approach
This accredited learning module explores how to initiate injectable therapy in a patient with type 2 diabetes who remains above their glycaemic target despite taking dual or triple oral therapy. The activity works through 3 in-depth case-studies: a patient with uncomplicated T2D, a patient with ASCVD risk, and a patient with established ASCVD.
Overcoming barriers to first injectable therapies in type 2 diabetes
Dr Tom Dover (Endocrinologist, Queensland Health) and Dr Ashraf Saleh (GP, Toowomba, Qld) discuss the role of injectable therapies in the ongoing management of type 2 diabetes, and outline methods to reduce barriers and improve patient outcomes.
